Search

Your search keyword '"MITSUMORI, Kenji"' showing total 137 results
Start Over Author "MITSUMORI, Kenji" Language english
137 results on '"MITSUMORI, Kenji"'

1. Impact of neurovascular bundle preservation on biochemical recurrence after robot-assisted radical prostatectomy for high-risk prostate cancer.

Author

Hagimoto, Hiroki, Kubota, Masashi, Matsui, Yoshiyuki, Sumiyoshi, Takayuki, Saito, Ryoichi, Segawa, Takehiko, Fukuzawa, Shigeki, Mitsumori, Kenji, Yoshida, Toru, Akao, Toshiya, Sekine, Yuya, Negoro, Hiromitsu, Kurahashi, Ryoma, Shimatani, Kimihiro, Sawada, Atsuro, Akamatsu, Shusuke, Kobayashi, Takashi, Goto, Takayuki, and Dai-CAD, the Daimonji Clinical Application Database

Subjects
RADICAL prostatectomy, PROPENSITY score matching, CANCER patients, PROSTATE-specific antigen, PROSTATE cancer
Abstract

Purpose: To evaluate functional and oncological outcomes in patients who underwent unilateral or bilateral nerve-sparing (NS) robot-assisted radical prostatectomy (RARP) for high-risk prostate cancer. Methods: The cohort comprised 2683 patients with clinical stage T1-4, N0M0 high-risk prostate cancer who underwent RARP in Japanese tertiary care centers from August 2011 to April 2023. High risk was defined using the European Association of Urology risk stratification criteria. Patients were classified as high risk if they had clinical stage T2c–T4, a serum prostate-specific antigen concentration (PSA) of > 20 ng/dL, or an International Society of Urological Pathology (ISUP) grade of 4–5. Patients were grouped into NS and non-NS surgery groups. Propensity score matching was performed (1:1 ratio) to reduce confounding bias. The primary outcome was biochemical recurrence (BCR)-free survival (BCR-FS). The impact of NS surgery on BCR-FS was examined in the propensity score-matched cohort using Cox proportional hazards regression. Results: The propensity score-matched cohort comprised 1722 patients. In the matched cohort, median follow-up was 31.9 months. The 5-year BCR-FS was 70.2% in the NS group and 71.9% in the non-NS group (HR 1.05; 95% confidence interval, 0.85–1.29). NS surgery did not increase the risk of BCR in subgroups of patients stratified according to ISUP grade, T stage, percent cancer core involvement, and PSA. Conclusion: Neurovascular bundle preservation during RARP for high-risk prostate cancer appears feasible without increasing the BCR rate. However, the retrospective study design carries the potential influence of selection bias. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

2. The third national Japanese antimicrobial susceptibility pattern surveillance program: Bacterial isolates from complicated urinary tract infection patients

Author

Kobayashi, Kanao, Yamamoto, Shingo, Takahashi, Satoshi, Ishikawa, Kiyohito, Yasuda, Mitsuru, Wada, Koichiro, Hamasuna, Ryoichi, Hayami, Hiroshi, Minamitani, Shinichi, Matsumoto, Tetsuya, Kiyota, Hiroshi, Tateda, Kazuhiro, Sato, Junko, Hanaki, Hideaki, Masumori, Naoya, Hiyama, Yoshiki, Yamada, Hiroki, Egawa, Shin, Kimura, Takahiro, Nishiyama, Hiroyuki, Miyazaki, Jun, Matsumoto, Kazumasa, Homma, Yukio, Kamei, Jun, Fujimoto, Kiyohide, Torimoto, Kazumasa, Tanaka, Kazushi, Togo, Yoshikazu, Uehara, Shinya, Matsubara, Akio, Shoji, Koichi, Goto, Hirokazu, Komeda, Hisao, Ito, Toru, Mori, Katsuhisa, Mita, Koji, Kato, Masao, Fujimoto, Yoshinori, Masue, Takako, Inatomi, Hisato, Takahashi, Yoshito, Ishihara, Satoshi, Nishimura, Kazuo, Mitsumori, Kenji, Ito, Noriyuki, Kanamaru, Sojun, Yamada, Daisuke, Hiroshi, Maeda, Yamashita, Masuo, Tsugawa, Masaya, Takenaka, Tadasu, Takahashi, Koichi, Oka, Yasuhiko, Yasufuku, Tomihiko, Watanabe, Shuji, Chihara, Yoshitomo, Okumura, Kazuhiro, Kawanishi, Hiroaki, Matsukawa, Masanori, Shigeta, Masanobu, and Koda, Shuntaro

Published
2020
Full Text
View/download PDF

4. Japanese nationwide surveillance in 2011 of antibacterial susceptibility patterns of clinical isolates from complicated urinary tract infection cases

Author

Ishikawa, Kiyohito, Hamasuna, Ryoichi, Uehara, Shinya, Yasuda, Mitsuru, Yamamoto, Shingo, Hayami, Hiroshi, Takahashi, Satoshi, Matsumoto, Tetsuro, Minamitani, Shinichi, Kadota, Jun-ichi, Iwata, Satoshi, Kaku, Mitsuo, Watanabe, Akira, Sunakawa, Keisuke, Sato, Junko, Hanaki, Hideaki, Tsukamoto, Taiji, Kiyota, Hiroshi, Egawa, Shin, Deguchi, Takashi, Matsumoto, Minori, Tanaka, Kazushi, Arakawa, Soichi, Fujisawa, Masato, Kumon, Hiromi, Kobayashi, Kanao, Matsubara, Akio, Wakeda, Hironobu, Amemoto, Yoshinosuke, Onodera, Shoichi, Goto, Hirokazu, Komeda, Hisao, Yamashita, Masuo, Takenaka, Tadasu, Fujimoto, Yoshinori, Tsugawa, Masaya, Takahashi, Yoshito, Maeda, Hiroshi, Onishi, Hiroyuki, Ishitoya, Satoshi, Nishimura, Kazuo, Mitsumori, Kenji, Ito, Toru, Togo, Yoshikazu, Nakamura, Ichiro, Ito, Noriyuki, Kanamaru, Sojun, Hirose, Takaoki, Muranaka, Takashi, Yamada, Daisuke, Ishihara, Satoshi, Oka, Hiroya, Inatomi, Hisato, Matsui, Takashi, Kobuke, Makoto, Kunishima, Yasuharu, Kimura, Takahiro, Ichikawa, Takaharu, Kagara, Ichiro, Matsukawa, Masanori, Takahashi, Koichi, Mita, Koji, Kato, Masao, Okumura, Kazuhiro, Kawanishi, Hiroaki, Hashimura, Takayuki, Aoyama, Teruyoshi, Shigeta, Masanobu, Koda, Shuntaro, Taguchi, Keisuke, and Matsuda, Yohei

Published
2015
Full Text
View/download PDF

6. Impact of neurovascular bundle preservation on biochemical recurrence after robot-assisted radical prostatectomy for high-risk prostate cancer

Author

Hagimoto, Hiroki, Kubota, Masashi, Matsui, Yoshiyuki, Sumiyoshi, Takayuki, Saito, Ryoichi, Segawa, Takehiko, Fukuzawa, Shigeki, Mitsumori, Kenji, Yoshida, Toru, Akao, Toshiya, Sekine, Yuya, Negoro, Hiromitsu, Kurahashi, Ryoma, Shimatani, Kimihiro, Sawada, Atsuro, Akamatsu, Shusuke, Kobayashi, Takashi, Goto, Takayuki, and Dai-CAD, the Daimonji Clinical Application Database

Published
2025
Full Text
View/download PDF

19. Micropapillary bladder cancer

Author

NISHIZAWA, KOJI, KOBAYASHI, TAKASHI, MITSUMORI, KENJI, IDE, YOSHIHIRO, WATANABE, JUN, and OGURA, KEIJI

Published
2005

36. 骨転移を有しない前立腺がん患者へのアンドロゲン除去療法による骨粗鬆症に対する経口ビスフォスフォネート製剤の予防効果について

Author

Kawahara, Takashi, Kobayashi, Takashi, Nishizawa, Koji, Kobori, Go, Mitsumori, Kenji, and Ogura, Keiji

Subjects
Prostate neoplasm, Osteoporosis, Bisphosphonate, Bone mineral, 494.9, Androgen deprivation
Abstract

We studied the short-term efficacy of alendronate, an oral bisphosphonates, on bone mineral density (BMD) during androgen deprivation therapy (ADT) in 45 nonmetastatic prostate cancer patients at the beginning of ADT (treatment group). All received alendronate five mg daily from the initiation of ADT. Lumber BMD was evaluated by dual energy X-ray absorptiometry, at baseline and after six months of treatment. Historical data on 24 patients with prostate cancer who received ADT without bisphosphonate administration were studied as controls (control group). BMD decreased in 13.9 and 45.8% of the patients in the treatment and control groups, respectively. Mean BMD changes in the lumber spine were +1.6 +/- 3.0% in the treatment group and -1.1 +/- 2.7% in the control group (p = 0.006). No pathological fractures occurred during the study period. No severe adverse effects were observed, but three patients could not continue alendronate treatment because of adverse events. Despite the short-term of this evaluation, our results showed that oral alendronate is an effective and safe treatment for preventing bone loss and increasing BMD in patients receiving ADT for prostate cancer., 目的:アンドロゲン除去療法は骨塩減少とそれに伴う病的骨折の潜在的な危険因子である。点滴ビスフォスフォネート製剤はアンドロゲン除去療法を受けている前立腺がん患者に対する骨塩量の減少を予防することが示されているが経口ビスフォスフォネート製剤については評価されていない。今回, われわれは経口ビスフォスフォネート製剤の1つであるアレンドン酸を骨転移を有しない前立腺がん患者に投与して骨塩量を測定し短期間での効果を検討した。対象と方法:治療群として45人の骨転移を有しない前立腺がん患者について検討した。アレンドロン酸を1日5mg経口投与し治療前, 治療半年後に腰椎の骨塩量を測定し比較検討した。対照群として24人の骨転移を有しない前立腺がん患者についても同様に検討を行った。結果:骨塩量の減少は治療群で13.9%, 対照群で45.8%に見られた。腰椎における骨塩量の変化は治療群で平均1.6%, 対照群で-1.1%であった(p=0.006)。治療期間内において病的骨折は認められず, 有害事象として重篤なものは認めなかったが副作用のため3例が内服継続困難であった。結語:短期間の検討であるにもかかわらず経口ビスフォスフォネート製剤であるアレンドロン酸は前立腺がん患者に対するアンドロゲン除去療法による骨塩量減少を予防するのに有効で安全な治療法であることが示唆された。(著者抄録)

Published
2008

41. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.

Author

Kobayashi, Takashi, Nishizawa, Koji, and Mitsumori, Kenji

Subjects
LUTEINIZING hormone releasing hormone agonists, PITUITARY hormone releasing factors, PROSTATE cancer, CANCER patients, CANCER treatment, ANDROGENS, PITUITARY hormones, HORMONE therapy, THERAPEUTICS
Abstract

Objective. To evaluate the process of hormonal recovery after cessation of luteinizing hormone-releasing hormone (LHRH) agonist treatment in patients who had received long-term LHRH agonist therapy for prostate cancer. Material and methods. Men who had successfully undergone androgen deprivation therapy with only monthly LHRH agonist therapy for > 30 months were enrolled and the administration of LHRH agonist was discontinued. Serum total testosterone, luteinizing hormone (LH), follicle-stimulating hormone (FSH) and prostate-specific antigen (PSA) were measured before the cessation of LHRH agonist therapy and every 4 weeks thereafter, and the administration of LHRH agonist remained suspended until the total testosterone level recovered to > 50 ng/dl. Results. Ten patients were enrolled in the study. The median (range) castration period and the levels of serum LH, FSH, total testosterone and PSA at cessation of therapy were 39 (30–56) months, 50 ng/dl in all cases. There were large variations in the times required for recovery of LH and FSH (30–100 days) and serum testosterone (30–330 days). PSA began to increase at various testosterone levels, and there was a large variation (0–83%; median 41%) in the ratio of the androgen suppression (testosterone [ABSTRACT FROM AUTHOR]

Published
2006
Full Text
View/download PDF

42. Prostate-specific antigen (PSA) complexed toα1-antichymotrypsin improves prostate cancer detection using total PSA in Japanese patients with total PSA levels of 2.0–4.0 ng/mL.

Author

Kobayashi, Takashi, Kamoto, Toshiyuki, Nishizawa, Koji, Mitsumori, Kenji, Ogura, Keiji, and Ide, Yoshihiro

Subjects
PROSTATE cancer, CLINICAL pathology, DISEASES in men, BIOPSY, PROSTATE-specific antigen, TUMOR antigens
Abstract

To assess the utility of prostate-specific antigen (PSA) complexed toα1-antichymotrypsin (PSA-ACT) in prostate cancer screening in Japanese men with a total PSA level of 2.0–4.0 ng/mL, as improving cancer detection in men with these total PSA levels is a challenge for clinical urologists.Total PSA and PSA-ACT were prospectively assessed and prostate biopsy recommended for patients who met either of two thresholds, i.e. a total PSA of≥ 2.0 ng/mL or a PSA-ACT of≥ 1.5 ng/mL. The diagnostic ability of total PSA and PSA-ACT, and free-to-total PSA ratio and prostate volume-adjusted density were evaluated by receiver operating characteristic (ROC) analysis.Of 1003 men enrolled, 547 met the biopsy criteria and a biopsy was taken in 315 (57.6%) patients. The area under the ROC curve for PSA-ACT (0.679) was significantly greater than that for total PSA (0.601,P = 0.04) and equivalent to that for the free-to-total ratio (0.686,P = 0.911) in 116 men, including 27 with cancer with total PSA levels of 2.0–4.0 ng/mL. PSA-ACT was more specific than the free-to-total ratio at a sensitivity of 95% (36% vs 18%,P < 0.05). The best variable for discriminating between cancer and benign disease in men with PSA levels of 2.0–4.0 ng/mL was PSA-ACT density (area under the curve 0.852) which provided 66% specificity at a sensitivity of 90%.PSA-ACT is better than total PSA and equivalent to the free-to-total ratio for detecting prostate cancer in men with PSA levels of 2.0–4.0 ng/mL, and is thus useful for reducing the number of unnecessary biopsies. [ABSTRACT FROM AUTHOR]

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results